Shortage of medicines: stock shortages or risks of shortages rising sharply in 2023

Shortage of medicines: stock shortages or risks of shortages rising sharply in 2023

THE difficulties in supplying medicines worsened further in 2023 France, approaching 5,000 reports of stock shortages and risks of stock shortages, according to a report from theMedicines Safety Agency (ANSM) published Friday.

In total, the ANSM recorded 4,925 declarations last year, compared to 3,761 in 2022, an increase of 30.9%. These reports more than doubled (+128%) compared to the 2,160 reports received in 2021.

The same medicine may be the subject of several reports by those involved in the distribution of products during the same year, recalls the ANSM in its press release.

If “all classes of drugs are concerned”, underlines the Agency, “cardiovascular drugs, nervous system drugs, anti-infectives and anti-cancer drugs are more particularly represented”.

The problem has been recurring for several years and affects many countries. Its causes are multiple: “Difficulties occurring during the manufacturing of raw materials or finished products, quality defects on medicines, insufficient production capacity, fragmentation of manufacturing stages, etc. », Lists the ANSM.

Aging of the population

Added to this is the increase in the need for medicines against a backdrop of aging populations. Concerning the most common antibiotic, amoxicillin, the ANSM has noted “for several weeks, a progressive improvement in the supply” of pharmacies and wholesale distributors “across the entire territory, in particular for pediatric presentations “.

Actors in the drug chain (industrialists, depositaries, wholesalers-distributorscommunity and hospital pharmacists) are nevertheless called upon to continue their efforts and “anticipate supplies now to guarantee coverage of needs at the end of this winter season”.

For other antibiotics, “such as azithromycin and pediatric cefpodoxime”, the situation has, however, become more fragile and manufacturers have also been asked to release their stocks, adds the ANSM.

All stakeholders committed this fall to a charter of good practices to share their data on the availability of medicines, under the aegis of the ANSM.

Source link